These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 16284533

  • 1. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.
    Jones SP, Qazi N, Morelese J, Lebrecht D, Sutinen J, Yki-Jărvinen H, Back DJ, Pirmohamed M, Gazzard BG, Walker UA, Moyle GJ.
    J Acquir Immune Defic Syndr; 2005 Dec 15; 40(5):565-72. PubMed ID: 16284533
    [Abstract] [Full Text] [Related]

  • 2. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy.
    Sievers M, Walker UA, Sevastianova K, Setzer B, Wågsäter D, Eriksson P, Yki-Järvinen H, Sutinen J.
    J Infect Dis; 2009 Jul 15; 200(2):252-62. PubMed ID: 19519254
    [Abstract] [Full Text] [Related]

  • 3. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients.
    Pace CS, Martin AM, Hammond EL, Mamotte CD, Nolan DA, Mallal SA.
    Antivir Ther; 2003 Aug 15; 8(4):323-31. PubMed ID: 14518702
    [Abstract] [Full Text] [Related]

  • 4. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
    Buffet M, Schwarzinger M, Amellal B, Gourlain K, Bui P, Prévot M, Deleuze J, Morini JP, Gorin I, Calvez V, Dupin N.
    J Clin Virol; 2005 May 15; 33(1):60-4. PubMed ID: 15797366
    [Abstract] [Full Text] [Related]

  • 5. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy.
    van der Valk M, Casula M, Weverlingz GJ, van Kuijk K, van Eck-Smit B, Hulsebosch HJ, Nieuwkerk P, van Eeden A, Brinkman K, Lange J, de Ronde A, Reiss P.
    Antivir Ther; 2004 Jun 15; 9(3):385-93. PubMed ID: 15259901
    [Abstract] [Full Text] [Related]

  • 6. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M.
    AIDS; 2000 Jul 28; 14(11):1591-600. PubMed ID: 10983646
    [Abstract] [Full Text] [Related]

  • 7. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.
    McComsey GA, Paulsen DM, Lonergan JT, Hessenthaler SM, Hoppel CL, Williams VC, Fisher RL, Cherry CL, White-Owen C, Thompson KA, Ross ST, Hernandez JE, Ross LL.
    AIDS; 2005 Jan 03; 19(1):15-23. PubMed ID: 15627029
    [Abstract] [Full Text] [Related]

  • 8. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
    Foudraine NA, de Jong JJ, Jan Weverling G, van Benthem BH, Maas J, Keet IP, Jurriaans S, Roos MT, Vandermeulen K, de Wolf F, Lange JM.
    AIDS; 1998 Aug 20; 12(12):1513-9. PubMed ID: 9727573
    [Abstract] [Full Text] [Related]

  • 9. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M.
    AIDS; 2000 Jul 28; 14(11):1601-10. PubMed ID: 10983647
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.
    Moore JD, Acosta EP, Johnson VA, Bassett R, Eron JJ, Fischl MA, Long MC, Kuritzkes DR, Sommadossi JP.
    Antivir Ther; 2007 Jul 28; 12(6):981-6. PubMed ID: 17926654
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors.
    Reiss P, Casula M, de Ronde A, Weverling GJ, Goudsmit J, Lange JM.
    HIV Med; 2004 Jan 28; 5(1):11-4. PubMed ID: 14731163
    [Abstract] [Full Text] [Related]

  • 15. Vitamin D attenuates nucleoside reverse transcriptase inhibitor induced human skeletal muscle mitochondria DNA depletion.
    Campbell GR, Pallack ZT, Spector SA.
    AIDS; 2013 Jun 01; 27(9):1397-401. PubMed ID: 23435299
    [Abstract] [Full Text] [Related]

  • 16. Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor.
    Domingo P, Sambeat MA, Pérez A, Ordoñez J, Rodriguez J, Vázquez G.
    Antivir Ther; 2003 Jun 01; 8(3):223-31. PubMed ID: 12924539
    [Abstract] [Full Text] [Related]

  • 17. First-line therapy and mitochondrial damage: different nucleosides, different findings.
    Blanco F, García-Benayas T, José de la Cruz J, González-Lahoz J, Soriano V.
    HIV Clin Trials; 2003 Jun 01; 4(1):11-9. PubMed ID: 12577192
    [Abstract] [Full Text] [Related]

  • 18. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
    Ribera E, Paradiñeiro JC, Curran A, Sauleda S, García-Arumí E, Castella E, Puiggròs C, Crespo M, Feijoo M, Diaz M, Del Saz SV, Planas M, Sureda D, Falcó V, Ocaña I, Pahissa A.
    HIV Clin Trials; 2008 Jun 01; 9(6):407-17. PubMed ID: 19203906
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Proteomic analysis identifies prohibitin down-regulation as a crucial event in the mitochondrial damage observed in HIV-infected patients.
    Ciccosanti F, Corazzari M, Soldani F, Matarrese P, Pagliarini V, Iadevaia V, Tinari A, Zaccarelli M, Perfettini JL, Malorni W, Kroemer G, Antinori A, Fimia GM, Piacentini M.
    Antivir Ther; 2010 Jun 01; 15(3):377-90. PubMed ID: 20516557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.